Source: Eur Respir J 2012; 40: 794-795
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Papiris Spyros A., Kagouridis Konstantinos, Kolilekas Likourgos, Triantafillidou Christina, Tsangaris Iraklis, Manali Effrosyni D.. Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation. Eur Respir J 2012; 40: 794-795

Member's Comments

No comment yet.

Related content which might interest you: Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Pirfenidone treatment for idiopathic pulmonary fibrosis (IPF): a comprehensive analysis of safety Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Osteoporosis treatment effectiveness in patient with idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes Source: Eur Respir Rev 2012; 21: 161-167 Year: 2012 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 The changing treatment landscape in idiopathic pulmonary fibrosis Source: Eur Respir Rev 2015; 24: 65-68 Year: 2015 Long-term nintedanib treatment in idiopathic pulmonary fibrosis (IPF): new data from INPULSIS-ON Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights Year: 2017 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Towards a better diagnosis of idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 108-113 Year: 2011 Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis Year: 2019 Idiopathic pulmonary fibrosis and pirfenidone Source: Eur Respir J 2010; 35: 728-729 Year: 2010